Sugi Predict

Sugi Predict / Compounds / SCHEMBL6819477

SCHEMBL6819477

SCHEMBL6819477

Cc1ccc(S(=O)(=O)N[C@@](N)(Cc2ccccc2)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.52
▸ CA9 Q16790 2/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ ATM Q13315 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.46
▸ CA2 P00918 2/20 0.45
▸ CA1 P00915 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CYP19A1 P11511 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ GAA P10253 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX12 P18054 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3056484 1.00 CA12 (0.52) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL6819636 1.00 CA12 (0.52) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL31039996 0.99 CA12 (0.51) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL30888830 0.99 CA12 (0.51) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL3991308 0.96 CA12 (0.49) CA12CA9CYP1A2CYP3A4ATM
P-Cymene SCHEMBL3994274 0.91 CNR2 (0.48) CA12CA9CYP1A2CYP3A4ATM
P-Cymene SCHEMBL14895952 0.89 CNR2 (0.46) CA12CA9CYP1A2CYP3A4ATM
Isopropylbenzene SCHEMBL12473841 0.89 CNR2 (0.44) CA12CA9CYP1A2CYP3A4ATM
P-Cymene SCHEMBL14895759 0.89 CNR2 (0.46) CA12CA9CYP1A2CYP3A4ATM
P-Cymene SCHEMBL1681678 0.89 CNR2 (0.46) CA12CA9CYP1A2CYP3A4ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025080946-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2025-04-17 — — WO disclosed
US-20240398770-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2024-12-05 — — US disclosed
WO-2023086696-A2 APPARATUS AND METHODS FOR CONTINUOUS FLOW SYNTHESIS OF CISATRACURIUM ODH IP Corp. (US) 2023-05-19 — — WO disclosed
US-11357757-B2 Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia ATROGI AB (SE) 2022-06-14 — — US disclosed
CN-114555564-A Antimalarial drugs 默沙东公司 2022-05-27 — — CN disclosed
WO-2004031168-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF OPTICALLY ACTIVE 3-AMINO-1-(2-THIENYL)-1-PROPANOL DERIVATIVES LONZA AG (CH) 2004-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357757-B2 Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia SLC5A2, SLC5A1, GPR119 CA12 3121/4885CA9 2094/4885CYP1A2 304/4885
US-20240398770-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA SLC5A2, SLC5A1, GPR119 CA12 3332/4885CA9 2307/4885CYP1A2 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.